Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Atlas Arteria ( (AU:ALX) ).
Atlas Arteria’s Dulles Greenway, operated through Toll Road Investors Partnership II, L.P (TRIP II), has filed a federal lawsuit against the Commonwealth of Virginia and other parties, alleging constitutional violations related to the taking of private property without compensation. This legal action is separate from an ongoing appeal regarding a 2024 rate case order. The dispute may impact the company’s operations and stakeholder interests, particularly concerning its U.S.-based infrastructure assets.
More about Atlas Arteria
Atlas Arteria (ASX:ALX) is a global entity engaged in the ownership, operation, and development of toll roads. It focuses on long-term value creation for investors through strategic management of its assets, which include significant toll road interests in France, the United States, and Germany. The company’s network contributes to reduced travel times and lower carbon emissions, enhancing community welfare.
YTD Price Performance: 8.56%
Average Trading Volume: 337
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.69B
See more data about ALX stock on TipRanks’ Stock Analysis page.
